Welcome to JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) June 10, 2025
LUO Juan, DUAN Su-rong, WANG Hua. Pedigree Analysis and Diagnosis of Congenital Dysfibrinogenemia: A Case Report[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(1): 171-174. DOI: 10.12182/20220160201
Citation: LUO Juan, DUAN Su-rong, WANG Hua. Pedigree Analysis and Diagnosis of Congenital Dysfibrinogenemia: A Case Report[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(1): 171-174. DOI: 10.12182/20220160201

Pedigree Analysis and Diagnosis of Congenital Dysfibrinogenemia: A Case Report

More Information
  • Corresponding author:

    WANG Hua, E-mail: wanghua@scu.edu.cn

  • Received Date: April 22, 2021
  • Revised Date: December 05, 2021
  • Available Online: January 23, 2022
  • Published Date: January 19, 2022
  •   Objective   To improve the understanding and diagnosis and treatment of congenital dysfibrinogenemia (CD) through analyzing the clinical data of a pediatric patient and his pedigree.
      Methods  The clinical manifestations, laboratory findings and treatment of a case of CD diagnosed at West China Second University Hospital, Sichuan University and those of its pedigree members were analyzed, and genetic tracing and follow-up were conducted on the patient and its pedigree.
      Results  The child has no clinical manifestations at the time of admission. Coagulation function examination showed normal prothrombin time (PT), normal activated partial thrombin time (APTT), significantly prolonged thrombin time (TT), fibrinogen activity (Fg: C<0.5 g/L) measured with the Clauss method, and fibrinogen antigen (Fg: Ag) measured at 2.8 g/L with PT algorithm. Gene sequencing results showed that heterozygous missense mutation c.901C>T (p.Arg301Cys) in exon 8 of FGG gene. Combined with the family history, the child was diagnosed with CD. During the follow-up of 4+ months, the patient did not present bleeding, abnormal coagulation or thrombosis, and the coagulation function did not show significant changes compared with the findings obtained on admission.
      Conclusion  The diagnosis of CD is confirmed mainly based on genetic testing and the treatment is characterized by the principle of precise individualized treatment. No special treatment is needed for patients presenting no clinical manifestations. However, it is important to provide thorough prenatal diagnosis and follow-up services for female patients planning for pregnancy so as to prevent miscarriage and complications caused by postpartum coagulation dysfunction.
  • [1]
    SHAPIRO S E, PHILLIPS E, MANNING R A, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenemia. Br J Haematol,2013,160(2): 220–227. DOI: 10.1111/bjh.12085
    [2]
    YAN J, DENG D, CHENG P, et al. Management of dysfibrinogenemia in pregnancy: A case report. J Clin Lab Anal, 2018, 32(3): e22319[2021-04-02]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816852/. doi: 10.1002/jcla.22319.
    [3]
    WEI A Q, WU Y Y, XIANG L Q, et al. Congenital dysfibrinogenemia caused by γAla327Val mutation: Structural abnormality of D region. Hematology,2021,26(1): 305–311. DOI: 10.1080/16078454.2021.1893977
    [4]
    DE MOERLOOSE P, CASINI A, NEERMAN-ARBEZ M. Congenital fibrinogen disorders: An update. Semina Thromb Hemost,2013,39(6): 585–595. DOI: 10.1055/s-0033-1349222
    [5]
    UNDAS A, CASINI A. Congenital structural and functional fibrinogen disorders: A primer for internists. Pol Arch Intern Med,2019,129(12): 913–920. DOI: 10.20452/pamw.15082
    [6]
    TISCIA G L, MARGAGLIONE M. Human fibrinogen: molecular and genetic aspects of congenital disorders. Int J Mol Sci, 2018, 19(6): 1597[2021-04-02]. https://doi.org/10.3390/ijms19061597.
    [7]
    DE MOERLOOSE P, NEERMAN-ARBEZ M. Congenital fibrinogen disorders. Semin Thromb Hemost,2009,35(4): 356–366. DOI: 10.1055/s-0029-1225758
    [8]
    SANTACROCE R, CAPPUCCI F, PISANELLI D, et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis,2006,l7(4): 235–240. DOI: 10.1097/01.mbc.0000224841.48463.be
    [9]
    罗莎莎, 杨丽红, 谢海啸, 等. 1例遗传性异常纤维蛋白原血症导致胎停育. 临床检验杂志,2020,38(3): 187–190.
    [10]
    IWAKI T, SANDIVAL-COOPER M J, PAIVA M, et al. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse. Am J Pathol,2002,160(3): 1021–1034. DOI: 10.1016/S0002-9440(10)64923-1
    [11]
    周伟杰, 闫婕, 邓东红, 等. 遗传性异常纤维蛋白原血症的诊断. 中华检验医学杂志,2020,43(4): 406–410. DOI: 10.3760/cma.j.cn114452-20191120-00681
    [12]
    DE MOERLOOSE P, BOEHLEN F, NEERMAN-ARBEZ M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost,2010,36(1): 7–17. DOI: 10.1055/s-0030-1248720
    [13]
    HARROP-GRIFFITHS W, COOK T, GILL H, et al. Regional anaesthesia and patients with abnormalities of coagulation: The Association of Anaesthetists of Great Britain & Ireland The Obstetric Anaesthetists’ Association Regional Anaesthesia UK. Anaesthesia,2013,68(9): 966–972. DOI: 10.1111/anae.12359
    [14]
    MUMFORD A D, ACKORYD S, ALIKHAN R, et a1. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol,2014,167(3): 304–326. DOI: 10.1111/bjh.13058
    [15]
    CASINI A, DE MOERLOOSE P, NEERMAN-ARBEZ M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost,2016,42(4): 366–374. DOI: 10.1055/s-0036-1571339
    [16]
    王甜甜, 邵静茹, 王杰, 等. 新型FGG基因突变导致遗传性纤维蛋白原缺陷症的研究. 中国实验血液学杂志,2021,29(2): 586–590.
    [17]
    MOSESSON M W, SIEBENLIST K R, MEH D A. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci,2001,936(1): 11–30. DOI: 10.1111/j.1749-6632.2001.tb03491.x
    [18]
    CASINI A, BLONDON M, LEBRETON A, et al. Natural history of patients with congenital dysfibrinogenemia. Blood,2015,125(3): 553–561. DOI: 10.1182/blood-2014-06-582866
    [19]
    HABETKATE F, SAMAMAM. Familial dysfibrinogenemia and thrombophilia report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost,1995,73(1): 151–161. DOI: 10.1055/s-0038-1653741
  • Cited by

    Periodical cited type(4)

    1. 唐勇,张福勇,蒋燕珍,吴崇荣,代洪飞,杨红海. 1例由p.Arg35Cys引起遗传性异常纤维蛋白原血症家系的研究. 右江医学. 2024(03): 215-220 .
    2. 成小慧. 遗传性异常纤维蛋白原血症家系表型和基因型研究. 中国现代药物应用. 2024(11): 64-67 .
    3. 李满桂,解承娟,周群,姜威. 高海拔地区FGA突变致遗传性异常纤维蛋白原血症的家系分析和诊治管理. 高原医学杂志. 2023(03): 25-28 .
    4. 罗欢,段苏容,王华. 新生儿标准肠外营养液配方使用规范. 四川大学学报(医学版). 2022(05): 941-944 .

    Other cited types(0)

Catalog

    Article views (844) PDF downloads (84) Cited by(4)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return